Those at highest risk for severe COVID-19 often least likely to get monoclonal antibodies, study fin…

People over age 65 at the highest risk for severe COVID-19 have often been the least likely to receive monoclonal antibodies (mAbs) — a highly effective treatment for the disease — both across and within U.S. states, according to new research co-authored by researchers from Harvard T.H. Chan…

Click here to view the original article.